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Summary23
We compared the effect of VIP on human blood monocytes infected with Salmonella24
Typhimurium 4/74 or stimulated with LPS. VIP (10-7 M) increased monocyte viability by25
24% and 9% when cultured for 24h with 4/74 or Salmonella LPS (100 ng/ml) respectively.26
Significantly increased (P< 0.05) numbers of 4/74 were also recovered from monocytes co-27
cultured with VIP after 6h post-infection (pi) and this remained high after 24h pi. Both 4/7428
and LPS increased (P <0.05) the concentration of TNF-α, IL-1β and IL-6 measured in 29
monocyte supernatants. However, LPS induced this effect more rapidly while, with the30
exception of IL-6, 4/74 induced higher concentrations (P< 0.05). VIP significantly decreased31
(P <0.05) TNF-α and IL-1β production by 4/74-infected monocytes after 6 pi, but only after 32
24h in LPS-cultured monocytes. This trend was reversed for IL-6 production. However,33
TNF-α and IL-1β production by 4/74-infected monocytes, cultured with VIP, still remained 34
higher (P< 0.05) than concentrations measured in supernatants cultured only with LPS. VIP35
also increased (P< 0.05) production of anti-inflammatory IL-10 in both 4/74 and LPS cultures36
after 24h. We also show a differential effect of VIP on the expression of TNFα and IL-6 37
receptors, since VIP was only able to decreased expression in LPS-stimulated monocytes but38
not in 4/74-infected monocytes.39
In conclusion, we show a differential effect of VIP on human monocytes infected with40
virulent Salmonella or stimulated with LPS. Our study suggests that the use of VIP in41
bacteraemia and/or sepsis may be limited to an adjunctive therapy to antibiotic treatment.42
43
44
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46
Introduction47
To date, most models of human sepsis involve murine studies or immortalised human48
immune cells, such as monocytic THP1 cells, stimulated with Lipopolysaccharide (LPS).49
However, the dynamic interaction of primary human blood monocyte with virulent Gram50
negative bacteria is likely to be different to that observed in these models, which essentially51
investigate endotoxaemia rather than bacteraemia. The general model of disease progression52
in sepsis proposes two phases. The first phase is characterised by uncontrolled production of53
inflammatory mediators leading to systemic inflammatory response syndrome (SIRS) (1-3)54
which leads to acute sepsis and may lead to hypoperfusion and organ collapse (termed septic55
shock). The second phase of disease is characterised by the production of a compensatory56
anti-inflammatory response syndrome (CARS), required to restore homeostasis but which can57
lead to secondary, nosocomial, infection (4-5, 3). The SIRS (acute) phase of sepsis is58
associated with high systemic concentrations of pro-inflammatory cytokines released by59
monocytes and macrophages, such as TNF-α, IL-1 and IL-6 (6) and acute sepsis is associated 60
with uncontrolled systemic inflammation. Thus, intervention which reduces the inflammatory61
immune response has been proposed as a rational therapeutic avenue. However, clinical trials62
in which this has been attempted have largely failed. One reason is that some agents used63
may be neutralised by the immune system or degraded by enzymes (7). Trials investigating64
inhibition of Tumor necrosis factor alpha (TNF-α) and interleukin 1β (IL-1β) were also 65
disappointing, probably due to high systemic concentrations of other cytokines and in some66
cases it seems that the cytokine status of patients was not measured prior to administration of67
specific cytokine inhibitors (8). Broad ranging anti-inflammatories such as glucocorticoids68
are also widely used in the treatment of sepsis but their effect is debateable probably due to69
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timing of therapy, dosage and the development of ‘steroid resistance’ by glucocorticoid70
receptors (9).71
Studies, to date, have suggested that VIP is an excellent therapeutic candidate against72
sepsis because (i) it is a natural product which does not induce an immune response, (ii) it is73
identical in all mammals apart from guinea pigs (10), (iii) it is easily synthesised in large74
quantities, (iv) in murine models of LPS-induced sepsis, low concentrations of VIP (<575
nmol) prevent mortality (11) and (v) VIP inhibits LPS-induced cytokine production in human76
THP-1 cells (12-14) indicating that results from animal models may translate into human77
medicine. VIP therefore has great potential as a cost effective therapeutic against Gram78
negative sepsis.79
Monocytes respond quickly to bacterial infection via inflammatory chemokines released in80
infected peripheral tissues (15). After recruitment into infected tissue, monocytes are81
subjected to signals from Th1 cells that respond to pathogen in tissues. This encounter results82
in the conversion of the monocytes to activated macrophages that are more competent in83
killing the pathogen and to initiate the systemic inflammatory response in order to clear the84
infection (16). Monocytes were used extensively in the past to study sepsis (17) and LPS-85
induced disease (18). However, nothing has been reported on the effect of VIP on the86
production of inflammatory mediators by human monocytes (rather than monocyte-like87
THP-1 cells) infected with virulent Gram negative bacteria, nor how this may compare to the88
effect of VIP when these monocytes are stimulated with LPS, since a discrepancy between89
the effect of VIP on these may have a significant impact on the use of VIP as a therapeutic.90
The aim of the work we describe was to compare the effect of VIP on the production of91
inflammatory mediators produced by human monocytes infected with Salmonella92
Typhimurium 4/74 or stimulated by LPS.93
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Materials and methods94
Salmonella and LPS95
S. Typhimurium 4/74 and LPS from S. Typhimurium SL1181 (Sigma-Aldrich, Poole, Dorset96
UK) were used to stimulate human monocytes in the study. In all experiments, S.97
Typhimurium 4/74 was cultured with monocytes at a multiplicity of infection of 10:1 (MOI98
=10). Monocytes were cultured with LPS at a concentration of 100 ng/ml, unless otherwise99
stated. Porcine VIP (95 % purity by HPLC) was obtained from Sigma-Aldrich, UK.100
101
Isolation of peripheral blood monocytes (PBM)102
Human blood was purchased from the blood transfusion service (Sheffield, UK). The blood103
was diluted with sterile PBS then gently poured onto Histopaque-1077 (Sigm-Aldrich, UK)104
prior to isolation of the buffer coat, as standard procedure. After appropriate washing steps,105
buffy coat supernatants were resuspended with appropriate amounts of cold MACS buffer106
and anti-CD14 antibody coated micromagnetic beads (Miltenyi Biotech, Bisley, Surrey UK)107
according to manufacturer’s instructions. The viability of isolated monocytes was assessed108
using Trypan blue (10% v/v) (Sigma) and was found to be > 90 % prior to use.109
110
Salmonella invasion and LPS stimulation assays111
The cultured monocytes were firstly washed with sterile PBS then the bacteria were added to112
the cultured monocytes at MOI of 10:1 at 37°C and 5% Co2 for 60 min. The cells were then113
washed and co-cultured with RPMI media contained 100μg/ml of gentamycin (Sigma-114
Aldrich, UK) with or without VIP (Sigma-Aldrich, UK) and placed in the incubator for a115
further 60 minutes. The cultured cells were washed again and the media was substituted with116
RPMI containing 25μg/ml of gentamycin with or without VIP (10-7 M) for a further 6 or 24h.117
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The cells were then washed three times with PBS at room temperature and then lysed using118
1% Triton X (Fisher Scientific LTD, Loughborough, UK) for 15 minutes at 37 OC.119
Intracellular bacterial counts were determined by serial dilution at different time points 2, 6,120
24 hours post infection. Viable bacterial cells counts were measured as colony forming units121
per ml (CFU/ml).122
In other experiments monocytes were cultured with LPS, with or without VIP (10-7 M), prior123
to isolation of supernatants for cytokine measurement or cell harvesting, for analysis of124
receptor expression. The dose effect of VIP on production of TNF-α and IL-10 by LPS-125
cultured monocytes was also measured in monocyte supernatants following co-culture of126
monocytes with LPS and different VIP concentrations ranging from 10-6-10-8 M.127
Monocyte survival assay128
The uptake of the fluorescent restriction dye Propidium iodide (PI) was used to measure the129
viability of cells under the experimental procedures described above. After 24h post-culture130
monocytes were incubated in PBS containing PI (10μg/ml) for 10 min. The number of non-131
viable cells (PI +) was assessed uaing FACSCanto II analyser (Becton Dickinson, USA).132
Samples were acquired using BD FACSDiva™ (BD Biosciences, USA) and analysed using133
CyFlogic 2.8 software, licensed to Nottingham University. Monocytes which had been134
immersed in ice cold (-20 0C) methanol for 30 min were used as a positive control and135
monocytes cultured in media only for 24h were used as a negative control. All experiments136
were performed in triplicate on 3 separate occasions.137
138
Measurement of cytokine concentration in monocyte supernatants139
ELISA kits (R&D Systems Abingdon, Oxford, UK) were used to measure TNFα, IL-1β, IL-140
6, IL-10 and IL-4 in the supernatants isolated from monocytes (2, 6 and 24h post-culture141
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infected with S. Typhimurium 4/74 or cultured with LPS, with or without co-culture with VIP142
(10-7 M). Supernatants isolated from monocytes cultured in media only were used as a143
negative control. All experiments were performed in triplicate on 3 separate occasions.144
145
Expression of cytokine receptors on monocyte membranes146
FACS analyses were performed to determine the effect of S. Typhimurium 4/74 infection or147
LPS culture on the expression of monocyte cytokine receptors and to determine whether, or148
not, this was affected by VIP (10-7 M). After 24h post-treatment, 1x106 monocytes, from each149
group, were washed 3 times in FACS buffer (EDTA 2mM; BSA 1% w/v) at 300g for 10 min150
per wash step. The cell pellets were then incubated with human Trustain FcX (Biolegend, San151
Diego, CA, USA) for 15 min to block FC receptors. After washing 3 times in FACS buffer,152
the cell pellets were re-suspended in FACS buffer containing relevant cytokine receptor153
antibodies for 45 min on ice in the dark. The antibodies used were as follows; Mouse anti-154
human TNF-α receptor (anti-TNFR.1/CD120) and isotype control (Mouse IgG2b.FITC) 155
(eBioscience, Santa Clara, CA, USA), Rat anti-human IL-6 receptor (IL-6R/CD126) and156
isotype control (Rat IgG2a.PE) (eBioscience, USA) and mouse anti-human IL-10 receptor157
(IL-10R/CD210) and isotype control (Mouse IgG1.FITC) (Biolegend, USA). In addition to158
this, some groups of monocytes were incubated with mouse anti-Human TLR4 antibody (or159
mouse IgG1.FITC isotype control antibody) to ascertain the effect of bacteria and VIP on a160
non-cytokine (but highly relevant) monocyte receptor.161
The concentration of all antibodies and FC blocking reagent are shown in Table 1. After162
antibody incubation, the cells were washed 3 times in FACS buffer and then re-suspended in163
0.2 ml of FACS buffer prior to analysis. on a FACSCanto II analyser ( BD, USA). Samples164
were acquired using the BD FACSDiva™ (BD Biosciences, USA) and analysed using the165
CyFlogic 2.8 software.166
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Statistical analysis167
ANOVA analyses with one way classification were performed to determine significance168
between experimental groups. Tukey’s post-hoc test was used to determine significant169
differences between groups at the 95% confidence limit (P = 0.05).170
171
Results172
Our results show that after 24h post infection (pi) of human monocytes with S. Typhimurium173
4/74, only 44% of cells remained viable, as measured by uptake of propidium iodide (Fig 1A)174
but this was significantly increased to 68% when co-cultured with VIP (10-7 M) . In175
comparison, when monocytes were stimulated with Salmonella LPS (100 ng/ml) for 24h,176
viability remained high at 79% but was further increased to 88% when co-cultured with VIP177
(Fig 1A). VIP also significantly (P <0.05) increased the numbers of bacteria recovered from178
monocytes at 6h pi by about 1.5 log and more were also recovered after 24h, but the179
difference was not significant (Fig 1B).180
We next compared the effect of VIP on the secretion of pro and anti-inflammatory cytokines181
by monocytes infected with 4/74 or cultured with LPS. S. Typhimurium 4/74 and LPS both182
significantly (P <0.05) increased the concentration of pro-inflammatory cytokines (TNF-α, 183
IL-1β and IL-6) measured in monocyte supernatants. LPS had a much more rapid effect on 184
monocytes and significantly increased cytokine levels within 2h, whereas similar increases185
were not measured in supernatants isolated from 4/74-infected monocytes at this time point186
(Fig 2A-E).187
TNF-α and IL-1β concentrations induced by Salmonella infection (Fig 2A and C) were much 188
greater than those induced by LPS culture (Fig 2B and D). Addition of VIP to 4/74-infected189
monocytes induced a significant decrease (P <0.05) in TNF-α production (Fig 2A) and IL-1β 190
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production (Fig 2C) at 6 and 24h pi but VIP only significantly decreased (P <0.05) TNF-α 191
and IL-1β production after 24h pi in LPS-cultured monocytes (Fig 2B and D respectively). 192
However even when 4/74-infected monocytes were cultured with VIP, the concentration of193
TNF-α or IL-1β remained at levels significantly greater (P <0.05) than those measured in 194
supernatants from monocytes stimulated with LPS which were not co-cultured in VIP.195
However, LPS induced a greater and much more rapid IL-6 response after 6h (Fig 2F)196
compared to IL-6 production by 4/74-infected monocytes, although this was equivalent after197
24h (Fig 2E). Conversely, VIP induced a significant decrease in IL-6 production by198
monocytes cultured with LPS after 6 and 24h (Fig 2F) but a significant reduction in IL-6199
produced by 4/74-infected monocytes was only measured after 24h post-culture in (Fig 2E).200
4/74 and LPS both significantly (P <0.05) increased the concentration of IL-4 produced by201
monocytes and this concentration was not significantly changed by the addition of VIP to the202
culture media (Fig 3A and B). Similarly, and LPS both significantly (P <0.05) increased the203
concentration of IL-10 produced by monocytes. However, the addition of VIP to the media in204
this case slightly increased IL-10 production by monocytes infected with 4/74, or cultured205
with LPS, after 6h but after 24h the increase was significant (P <0.05) with 4/74 inducing206
much higher levels of IL-10 than that measured in the supernatants of LPS stimulated207
monocytes (Fig 3C and D).208
Since VIP had little effect on either LPS-induced TNF-α or IL-10 production after 6h, we 209
investigated whether a dose effect of VIP could be measured at this time point. VIP did have210
a dose-dependent effect on LPS-stimulated production of inflammatory (TNF-α) and anti-211
inflammatory (IL-10) cytokines. When added at concentration ranges from 10-6, 10-7 and 10-8212
M, VIP increased the concentration of LPS-induced TNF-α (Fig 4B) but VIP only 213
significantly inhibited ( P < 0.05) LPS-induced TNF-α production by monocytes when added 214
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at a concentration of 10-6 M (Fig 4A). We also observed a dose effect of VIP on IL-10215
production but the dynamics of this were very different to those measured for TNF-α. In this 216
case, VIP at 10-7 or 10-8 M increased IL-10 concentration in the supernatants of LPS-217
stimulated monocytes above that measured in supernatants isolated from monocytes cultured218
only with LPS (Fig 4B) and at 10-8 M, this increase was significant (P <0.05).219
Finally we compared the effect of VIP on expression of cytokine receptor proteins on the220
surface of monocytes infected with 4/74, or cultured with LPS for 6h. Our results show that221
both TNFR.1 (Fig 5A) and IL-6R (Fig 5B) were increased on the surface of monocytes222
infected with 4/74, or cultured with LPS for 6h. VIP had no effect on this expression by223
Salmonella-infected monocytes but did decrease expression of both receptors on the surface224
of monocytes cultured with LPS (Fig 5A and B). Expression of IL-10R did not increase225
above isotype control levels on the surface of monocytes infected with S. Typhimurium 4/74226
and this was not altered by VIP. However, LPS stimulated an increase in IL-10R expression227
on the surface of monocytes and this upregulation of receptor was inhibited by VIP (Fig 5C).228
We then investigated the effect of VIP on expression of TLR4 which is critical receptor in229
LPS detection and innate immune response but is involved in LPS (rather than cytokine)230
detection. In these experiments we found that both Salmonella infection or LPS culture231
upregulated TLR4 expression by monocytes and in both cases this was reduced when the232
cells were co-cultured with VIP (Fig 5D).233
234
Discussion235
To date, most studies which have investigated the effect of VIP on bacterial-induced236
inflammatory pathways have involved LPS and either murine macrophages (19,20), murine237
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models of disease (11) or immortalised human THP-1 monocytes (12-14). Although LPS is a238
very strong immunogen it lacks the genetic complexity of intact bacteria. For example,239
bacteria express a number of other substances such as flagellin, CpG oligodeoxynucleotides,240
peptidoglycans and lipoproteins which also initiate an inflammatory response. They also241
utilse sophisticated secretion systems to invade and survive in cells and which encode242
proteins that may down-regulate host immune responses. There are very few reported studies243
which have investigated the effect of whole viable bacteria on human monocytes and the role244
of VIP in this system as a potential therapeutic in sepsis.245
In this current study we show that VIP increased the viability of monocytes infected with S.246
Typhimurium 4/74 or exposed to LPS. The greatest effect of VIP on viability was when247
monocytes were infected with Salmonella, with less than half remaining viable when cultured248
with 4/74 for 24h, but in co-culture with VIP viability increased by >20%. VIP has249
previously been reported to prevent LPS-induced cell death in rat neuronal mesenteric cells250
(21) and our study is therefore in accordance with this. S. Typhimurium SL1344 has been251
previously reported to induce apoptosis in human monocyte-derived macrophages (22) and252
also in the human monocytic cell line, U937 (23). However, a positive correlation between253
increased apoptosis of blood monocytes and increased survival of sepsis patients has been254
previously reported (24) and elevated monocyte numbers has also been reported to correlate255
with sepsis (25). It is possible, therefore, that the physiological response to sepsis is to reduce256
some of the capacity of the immune system (monocytes) to produce inflammatory mediators257
by inducing apoptosis in these cells. If this is the case, then administration of VIP to patients258
who have Gram negative bacteraemia may have a detrimental effect. It is probably also the259
case that the increase in Salmonella survival associated with VIP that we have shown is due260
to the increased survival of monocytes. However, addition of VIP to culture media was261
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associated with decreased production of inflammatory cytokines (TNFα, IL-1β and IL-6) and 262
an increase in anti-inflammatory IL-10. Early studies have shown that TNFα, IL-1β were 263
upregulated in the blood of volunteers in which LPS was intravenously administered (26-27).264
Following meta-analysis, Lv et al., (28) reported that TNFα may be a useful biomarker of 265
neontal sepsis. Meta-analyses have also indicated that TNF-α therapy may reduce mortality if 266
adminiistered prior to shock and may also have therapeutic benefit in patients with high IL-6267
titres (29) and that in paediatric sepsis, TNFα levels could be used as a biomarker as it 268
strongly correlates with Gram negative culture from patients (30). This latter study may be269
highly relevant to ours since we show that VIP reduces TNFα production by 4/74-infected 270
monocytes, although it would also suggest that TNFα production is a double-edged sword in 271
that it probably is needed to kill bacteria also. As such, VIP may be a useful adjunctive272
therapy to antiobiotic treatment. A study by Gogos et al., (31) reported that IL-10273
concentration was postively correlated with the onset of sepsis and that high IL-10/TNF- α 274
ratio indicated a poor prognosis. High circulating levels of IL-6 and IL-10 have also been275
associated with mortaility in other studies (32, 25). Since we show that VIP inhibits IL-6 but276
increases IL-10 production by monocytes it is difficult to say what effect this may have in277
vivo and it is also possible that this could be beneficial or detrimental depending on the phase278
of disease (SIRS or CARS). In a study of 178 biomarkers for sepsis, it was reported that only279
5 had a specificity and sensitivity > 90% (33) and none of these biomarkers were cytokines280
we report here. However, the cytokines we have studied are known to stimulate production of281
most of these biomarkers and so inhibiting cytokines during ongoing bacterial infection may282
have a therapeutic, down-stream, effect.283
We also studied the effect of VIP on the expression of important monocyte receptors.284
Surprisingly, we found that VIP was unable to suppress the increased expression of TNFR.1,285
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or IL-6R on the surface of monocytes infected with 4/74 but was able to do so when286
monocytes were stimulated with LPS. We also show a very different response in expression287
of IL-10R, on the surface of monocytes, when comparing S. Typhimurium 4/74 infection288
with LPS culture. In this case, 4/74-infected monocytes were unable to upregulate IL-10R289
and this was not altered by co-culture with VIP. However, LPS increased IL-10R expression290
and this was decreased by co-culture with VIP. Therefore, the effect of VIP differs greatly in291
respect to expression of cytokine receptors depending on whether human monocytes are292
infected with virulent Gram negative bacteria or stimulated with LPS. This suggests that293
bacterial factors, other than LPS, may prevent the inhibitory effect of VIP on expression of294
these receptors and may indicate that administration of VIP, during sepsis, could be less295
effective if the patient has ongoing Gram negative infection. TLR4 activation of NFKB has296
long been associated with the development of sepsis (34-35) and it is perhaps significant that297
we show that VIP inhibits TLR4 expression in monocytes stimulated with LPS but also298
following infection by 4/74. Previously this effect has only been reported in human299
monocytic THP-1 cells stimulated with LPS from Escherichia Coli or Porphyromonas300
Gingivalis (14), While VIP also inhibits TLR4 mRNA (although surface protein was not301
measured) in murine macrophages stimulated with LPS (36). Therefore, we show that VIP302
inhibits the initial detection and down-stream transcriptional response to both virulent303
Salmonella and LPS and is most likely the reason why VIP inhibits production of the304
inflammatory cytokines we have measured in this study.305
In conclusion our study suggests that VIP may have therapeutic value in human sepsis by306
inhibiting the production of inflammatory cytokines and cytokine receptors by blood307
monocytes during endotoxaemia, although the timing of VIP intervention (during the SIRS or308
CARS phase of disease) may be critical. However, we show that VIP does not down-regulate309
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some important cytokine receptors when monocytes are infected with virulent Salmonella310
and, although it decreases the production of inflammatory cytokines by these cells, the level311
of cytokines still remain higher than that induced by LPS alone. Furthermore, VIP increases312
the viability of infected monocytes which may have an overall detrimental effect during313
bacteraemia/sepsis. Therefore, we suggest that VIP would probably need to be administered314
as an adjunctive therapy to antibiotic treatment rather than a ‘stand-alone’ therapy as315
suggested by earlier murine studies using LPS.316
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Figure Legends430
431
Figure 1. VIP increases the viability of both human monocytes and S. Typhimurium432
4/74 after 24h post-infection433
(A); FACS analysis was performed to show that VIP (10-7 M) increased monocyte survival434
after 24 pi with S. Typhimurium 4/74 (MOI = 10) or following culture with Salmonella LPS435
(100 ng/ml) for 24h. * = significant increase (P < 0.05) in the numbers of viable monocytes436
co-cultured with VIP and S. Typhimurium or LPS. Positive control = monocytes cultured437
with methanol. Negative control = monocytes cultured in media only over the same time438
period and , as an additional control VIP (10-7M) alone was added to monocytes cultures but439
this had no effect on monocytes survival (data not shown). Monocytes were cultured with the440
fluorescent restriction dye Propidium iodide (1 μg/ml) to assess cell death. 441
(B); Shows the number of viable S. Typhimurium 4/74 recovered from monocytes after 2-24h442
pi, with or without VIP (10-7 M). * = significant increase (P < 0.05) in the number of S.443
Typhimurium 4/74 recovered from infected monocytes co-cultured with VIP after 24h.444
Histograms show data of mean values calculated from triplicate experiments performed on445
three separate occasions. Error bars show standard deviation (SD) from the mean.446
447
Figure 2. VIP inhibits the production of TNF-α and IL-β by human monocytes infected 448
with S. Typhimurium 4/74 but the concentration of both remain significantly higher449
than TNF-α and IL-β stimulated by LPS 450
ELISA analyses showing that VIP (10-7 M) significantly inhibited (P <0.05) TNF-α (A) and 451
IL-1β (C) production by human monocytes infected with S. Typhimurium 4/74 (MOI =10) at452
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6 and 24h pi. VIP also significantly inhibited (P <0.05) TNF-α (B) and IL-1β (D) production 453
by human monocytes following culture with LPS (100 ng/ml) for 24h. VIP significantly (P <454
0.05) inhibited production of IL-6 by monocytes infected with S. Typhimurium 4/74 at 24h pi455
(E) but VIP inhibited IL-6 production by monocytes cultured with LPS for both 6 and 24h456
(F). In 4/74-infected monocytes cultured with VIP, TNF-α and IL-1β (A and C) 457
concentrations remain significantly higher (P <0.05) than those measured in monocyte458
supernatants cultured only with LPS (B and D). Negative controls = monocytes cultured in459
media only over the same time periods and, as an additional control, VIP (10-7M) alone was460
added to monocytes cultures but this had no effect on cytokine production (data not shown).461
* = significant decrease (P < 0.05). Histograms show data of mean values calculated from462
triplicate experiments performed on three separate occasions. Error bars show standard463
deviation (SD) from the mean.464
465
Figure 3. VIP has no effect on IL-4 production by human monocytes infected with S.466
Typhimurium 4/74 or cultured with LPS but increases production of IL-10 following467
either treatment.468
ELISA analyses showing that VIP (10-7 M) had no effect on IL-4 production by human469
monocytes infected with S. Typhimurium 4/74 (MOI =10) (A) or following culture with470
Salmonella LPS (100 ng/ml) (B) for 2-24h. VIP significantly increased (P <0.05) IL-10471
production by monocytes infected with S. Typhimurium 4/74 after 24h pi. (C). VIP also472
increased IL-10 production by monocytes cultured with LPS for 6 and 24h and after 24h this473
increase was significant (P <0.05) (D). Negative controls = monocytes cultured in media only474
over the same time periods and, as an additional control, VIP (10-7M) alone was added to475
monocytes cultures but this had no effect on cytokine production (data not shown). * =476
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significant decrease (P < 0.05). Histograms show data of mean values calculated from477
triplicate experiments performed on three separate occasions. Error bars show standard478
deviation (SD) from the mean.479
480
Figure 4. VIP dose dependently changes TNF-α and IL-10 production by LPS-cultured 481
cells.482
( (A); ELISA analyses showing that decreased TNFα production by monocytes, infected with 483
S. Typhimurium 4/74 for 6h pi, was correlated with increased VIP concentration (10-6-10-8484
M). * = significant decrease in TNFα (P < 0.05) compared with TNFα production by 485
monocytes cultured with LPS alone. (B); Decreased IL-10 production by monocytes infected486
with S. Typhimurium 4/74 for 6h pi was correlated with increased VIP concentration (10-6-487
10-8 M). * = significant increase in IL-10 (P < 0.05) compared with IL-10 production by488
monocytes cultured with LPS alone. Negative controls = monocytes cultured in media only489
over the same time periods and, as an additional control, VIP (10-7M) alone was added to490
monocytes cultures but this had no effect on cytokine production (data not shown).491
Histograms show data of mean values calculated from triplicate experiments performed on492
three separate occasions. Error bars show standard deviation (SD) from the mean.493
494
495
496
497
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Figure 5. VIP inhibits expression of cytokine receptors on the surface of human498
monocytes cultured with LPS but not following infection with S. Typhimurium 4/74.499
FACS analyses showed that VIP (10-7 M) had no effect on the expression of TNFR.1 (A);500
IL-6R (C) or IL-10R (E) on the surface of human monocytes infected with S. Typhimurium501
4/74 (MOI =10) after 6h pi. However, VIP inhibited expression of TNFR.1 (B); IL-6R (D) or502
IL-10R (F) on the surface of human monocytes cultured with Salmonella LPS (100 ng/ml)503
after 6h pi. Conversely VIP (10-7 M) inhibited expression of TLR4 on the surface of504
monocytes infected with S. Typhimurium 4/74 (G) or following culture with LPS (H) for 6h.505
= Isotype control; = Monocytes cultured with S. Typhimurium 4/74 or LPS;506
= Monocytes cultured with S. Typhimurium 4/74 or LPS and VIP. FACS histograms507
are representative of data obtained from triplicate experiments performed on three separate508
occasions.509
510
Table 1. The concentration of antibodies and isotype controls used in cytokine receptor511
FACS analyses.512
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